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Background: Melanocortin-1 receptor (MC1R) gene variants are very common and are associated with melanoma
risk, but their contribution to melanoma risk prediction compared with traditional risk factors is unknown. We
aimed to 1) evaluate the separate and incremental contribution of MC1R genotype to prediction of early-onset
melanoma, and compare this with the contributions of physician-measured and self-reported traditional risk factors,
and 2) develop risk prediction models that include MC1R, and externally validate these models using an
independent dataset from a genetically similar melanoma population.
Methods: Using data from an Australian population-based, case-control-family study, we included 413 case and
263 control participants with sequenced MC1R genotype, clinical skin examination and detailed questionnaire. We
used unconditional logistic regression to estimate predicted probabilities of melanoma. Results were externally
validated using data from a similar study in England.
Results: When added to a base multivariate model containing only demographic factors, MC1R genotype improved
the area under the receiver operating characteristic curve (AUC) by 6% (from 0.67 to 0.73; P < 0.001) and improved
the quartile classification by a net 26% of participants. In a more extensive multivariate model, the factors that
contributed significantly to the AUC were MC1R genotype, number of nevi and previous non-melanoma skin
cancer; the AUC was 0.78 (95% CI 0.75-0.82) for the model with self-reported nevi and 0.83 (95% CI 0.80-0.86) for
the model with physician-counted nevi. Factors that did not further contribute were sun and sunbed exposure and
pigmentation characteristics. Adding MC1R to a model containing pigmentation characteristics and other self-
reported risk factors increased the AUC by 2.1% (P = 0.01) and improved the quartile classification by a net 10%
(95% CI 1-18%, P = 0.03).
Conclusions: Although MC1R genotype is strongly associated with skin and hair phenotype, it was a better
predictor of early-onset melanoma than was pigmentation characteristics. Physician-measured nevi and previous
non-melanoma skin cancer were also strong predictors. There might be modest benefit to measuring MC1R
genotype for risk prediction even if information about traditional self-reported or clinically measured pigmentation
characteristics and nevi is already available.
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Melanoma is one of the most common cancers and
a leading cause of cancer death in young adults of
European origin [1,2]. People identified as being at high
risk of melanoma could likely benefit from regular skin
checks and interventions to improve sun-protection be-
haviours [3,4]. Phenotypic characteristics (e.g. hair, eye
and skin colour, skin sensitivity to sunlight, number of
nevi (moles)), family history, past sun exposure and past
history of skin cancer are usually the basis for discrimin-
ating individual risk of melanoma [5-7]. However, given
the decreasing costs and increasing use of genetic test-
ing, it is becoming more feasible to incorporate genetic
risk factors into clinical risk prediction tools. Low pene-
trant genetic variants for the melanocortin-1 receptor
(MC1R) gene [8,9] are very common in populations of
European origin [10,11] and some of these variants
have been associated with a 1.5 to 4-fold increased risk
of melanoma [12-15]. MC1R variants are associated
with sun-sensitive phenotypes but the association with
melanoma appears to be mediated also through non-
pigmentary pathways [12,15]. To date, only three, prelim-
inary, melanoma risk prediction models have included
MC1R genotype [16-18]. No study has formally assessed
the contribution of MC1R genotype to melanoma risk
prediction compared with traditional factors.
The Australian Melanoma Family Study is a multi-
centre, population-based, case-control-family study of
early-onset melanoma (diagnosis before 40 years of age)
that has comprehensive data for MC1R genotype and
traditional risk factors including phenotype, UV (ultra-
violet) radiation and clinically measured nevus counts
[19]. Using data from this study, we aimed to 1) evaluate
the separate and incremental contribution of MC1R
genotype to prediction of early-onset melanoma, and
compare this with the contributions of physician-mea-
sured and self-reported traditional risk factors, and 2)
develop risk prediction models that include MC1R, and
externally validate these models using an independent




The Australian Melanoma Family Study design, recruit-
ment, data collection and participant characteristics have
been previously detailed [19]. Cases and controls were
living in Brisbane, Sydney or Melbourne, which com-
prise about 50% of Australia’s population. Approval for
the study was obtained from the ethics committees of
The University of Sydney, The University of Melbourne,
The University of Queensland, Cancer Council Victoria,
Queensland Cancer Register and Cancer Council NSW.
All participants provided written, informed consent.Case participants
Cases were identified from population-based state
cancer registries, diagnosed between 1st July 2000 and
31st December 2002 at ages 18–39 years with inci-
dent, histopathologically-confirmed, first-primary inva-
sive cutaneous melanoma. A total of 629 cases were
recruited; participation was 54% of those eligible and
76% of those contactable.
Control participants
Population controls were aged between 18 and 39 years
at the time of approach and had no history of inva-
sive or in situ melanoma. They were selected from
the electoral roll (registration to vote is compulsory
for Australian citizens aged 18 years and over) and
were frequency-matched to cases by city, age and sex.
A total of 240 population controls were recruited;
participation was 23% of those apparently eligible and
42% of those contactable.
Eligible spouse or friend controls were a spouse, part-
ner, or friend nominated by a case as a potential control
participant. They were eligible if they were at least
18 years of age and had no history of invasive or in situ
melanoma; there were no other age, sex or residency re-
strictions. A potential control was nominated by 59% of
cases. A total of 295 spouse or friend controls were
recruited; participation was 80% of those nominated.
Population-controls and spouse or friend-controls were
combined into one control group as done previously
[15,19].
Questionnaire data
Data were collected by telephone interview using a
structured questionnaire, which included detailed ques-
tions on sun exposure, phenotype, residence history,
demographic information, ancestry and diagnoses of
cancer and non-melanoma skin cancers (basal cell car-
cinoma and squamous cell carcinoma) [19,21]. Partici-
pants also reported their skin colour and type, eye
colour, natural hair colour at age 18 years, usual tanning
and sunburn response to prolonged or repeated expo-
sure to sunlight in summer, sunbed use, the number of
nevi covering the body (described pictorially as none,
few, some, many), freckling in childhood and adulthood,
and nevus count on the back. Reported melanoma in
relatives was verified where possible [19].
Clinical skin examinations
All case and control participants were invited to attend
clinical skin examinations, which were conducted at
dermatology clinics in Brisbane, Sydney, and Melbourne
by dermatology trainees trained on the study protocol. A
clinical skin examination was completed by 73% of cases,
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controls.
Measurement of nevi was based on international
guidelines [22]. Separate counts were made for melano-
cytic nevi of 2-5 mm and >5 mm, raised nevi of >2 mm,
and clinically atypical nevi of >2 mm, on 30 body sites.
The number of solar lentigines on the upper back was
recorded by using a 6-level picture scale. Natural hair
colour at age 18 and eye colour were recorded using wig
hair swatches and eye photographs. Reflected skin
colour, a correlate of melanin content [23], was recorded
using a hand-held reflectance spectrophotometer with
standard reflectance at 685 nm. The multi-wavelength
data quantify colour using the Commission Interna-
tionale de l'Éclairage L* a* b* colour space parameters
[24]. Inner arm L* values describe base skin colour,
b* values describe tanning, and a* values describe ery-
thema [23-25].
MC1R genotyping and classification
Blood samples were requested from all participants and
were obtained from 597 (95%) cases, 220 (92%) popula-
tion controls, and 256 (87%) spouse/friend controls. The
methods for MC1R genotyping and classification have
been described in detail elsewhere [15]. Briefly, we se-
quenced MC1R and classified variants D84E, R142H,
R151C, I155T, R160W, D294H as ‘R’ variants and all
other variants excluding synonymous changes and non-
coding changes as ‘r’ variants. R variants have been
shown to be strongly associated with the presence of
‘red hair colour phenotype’ (red hair, fair skin, freckling,
poor sun sensitivity), whereas r variants generally have a
weaker association with red-hair colour phenotype [12].
The association of the individual MC1R variants with
melanoma risk in this sample has been described previ-
ously [15].
When MC1R genotype was added to the statistical
models, it was added together as a group of seven separ-
ate variables: one for each of the six ‘R’ variants D84E,
R142H, R151C, I155T, R160W, D294H, and one variable
for all ‘r’ variants combined. Each of these variables
was formatted to indicate the number of variant al-
leles (i.e. 0,1,2).
Statistical analysis
In order to compare the contribution of MC1R genotype
with all self-reported and clinical traditional risk factors
simultaneously, we restricted this analysis to case and
control participants who had: complete questionnaire
data for the main risk factors examined, a clinical skin
examination, MC1R genotype, self-reported exclusive
European ancestry, and were aged < 45 years at inter-
view. After exclusions, 676 participants remained for the
analysis: 413 cases and 263 controls (115 population-controls and 148 spouse or friend controls). Data were
analysed using SAS version 9.2 (SAS Institute, Cary NC)
and statistical significance was inferred at two-sided
P < 0.05.
Model development
In the ‘base’ model, melanoma status was the outcome
variable and covariates included demographic factors:
age (quadratic), sex, city of recruitment (Brisbane,
Sydney, Melbourne), and self-reported European an-
cestry (British/northern, southern, eastern/mixed/other
European) to account for any difference in MC1R al-
lele frequencies across ethnic groups [11].
We added MC1R genotype and traditional risk factors
separately to the base model to evaluate their individual
contribution to risk prediction. We also added the risk
factors incrementally to the base model in order of their
contribution to the area under the receiver operating
characteristic (ROC) curve (AUC). To examine the con-
tribution of traditional pigmentation characteristics, we
created a pigmentation-related propensity-to-melanoma
score (‘pigmentation score’) continuous variable that
summarizes the contribution of six correlated, categor-
ical phenotypic variables, including self-reported ability
to tan, propensity to sunburn, childhood freckling, skin
colour, eye colour, and hair colour [15]. For the more
objectively-measured pigmentation score, the last three
self-reported variables were replaced with physician-
measured skin reflectance, eye colour, and hair colour.
Other self-reported variables that were tested in the
models were number of nevi fitted as a categorical
variable (none, few, some, many), previous diagnosis of
non-melanoma skin cancer (yes, no), and ultraviolet
(UV) radiation related exposures: total childhood sun
exposure hours (quartiles), childhood blistering sun-
burns (none, ≤ 8, > 8) and lifetime sunbed use (none,
1–10, >10 sessions). The two childhood measures were
chosen over other sun exposure measures such as life-
time, adulthood, weekday and holiday sun exposure,
because they were more predictive of melanoma in
our study sample. Other physician-measured variables
that were tested in the models were separate nevus
counts (≥ 2 mm, 2–5 mm, ≥ 5 mm, dysplastic, raised)
and solar lentigines. We also included confirmed family
history of melanoma in a first-degree relative.
Measures of model performance
As measures of discrimination, i.e. the ability of a model
to discriminate those who will develop melanoma from
those who will not, we calculated: the AUC, which is
equivalent to the concordance (c) statistic; the net re-
classification improvement (NRI); discrimination slope;
and the integrated discrimination index (IDI) [26-29]. To
assess calibration, i.e. the agreement between observed
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goodness-of-fit test [26,30]. These measures were based
on predicted probabilities of melanoma from the uncondi-
tional logistic regression models described above.
The AUC is equal to the probability that, for one case
and one control chosen at random from the data set, the
predicted probability of melanoma is higher for the case
than for the control, and ranges from 0.5 (equivalent to
a coin toss) to 1.0 (perfect discrimination). The NRI
quantifies overall improvement in model sensitivity and
specificity. A net improvement in risk classification im-
plies upward reclassification of case participants and
downward reclassification of control participants. The
NRI was calculated by first fitting a ‘base model’ which
grouped participants into quartiles of their predicted
probability of melanoma; these quartile distributions
were then compared to the ‘comparison model’. Im-
provement in sensitivity represents net reclassification of
more cases into higher quartiles, improvement in speci-
ficity represents net reclassification of controls into
lower quartiles, and overall improvement in classifica-
tion combines the improvements in sensitivity and
specificity. In the absence of clinically meaningful cut-
points, we used quartiles to define risk categories as
done elsewhere [27]. We also calculated the ‘category-
free’ NRI, for which the definition of upward or down-
ward movement is simplified to indicate any increase or
decrease in probabilities of the outcome [31]. Discrimin-
ation slope was calculated as the difference between the
mean predicted probability for cases and controls, and
the IDI was calculated as the difference between dis-
crimination slopes between the base and comparison
models; both of these measures do not require prede-
fined risk categories. As measures of overall model per-
formance, we estimated the Brier score and Nagelkerke’s
R2, which are measures of how well future outcomes are
likely to be predicted by the model [30]; a higher
Nagelkerke’s R2 and a lower Brier score indicates better
predictability of the model.
As a measure of internal validation, we used 100 boot-
strap samples to estimate the AUC and Nagelkerke’s R2
for the final models. Odds ratios (OR) for melanoma
and their 95% confidence intervals were estimated using
unconditional logistic regression models.
External validation
We performed external validation of the final regression
models using a population-based case–control study of
melanoma from a geographically defined area of Yorkshire
and the Northern region of the United Kingdom [32].
Case participants had incident pathologically confirmed
invasive melanoma diagnosed between September 2000
and December 2005 (67% case participation). Control par-
ticipants were identified from the cases’ family doctors(55% response) and were frequency-matched to cases by
age and sex. A total of 841 case participants and 452
control participants, aged between 18 and 76 years, were
included in this analysis. This study was conducted in tan-
dem with the Australian case–control study and used a
common protocol for collection of phenotype and sun ex-
posure measures to facilitate comparisons among the
datasets. We handled the data variables and analysis in the
same way for both datasets.Results
Characteristics of the study sample
Demographic characteristics and selected risk factors of
early-onset cases and controls are shown in Table 1.
Fifty-eight percent of cases and 40% of controls had at
least one R allele. A previous non-melanoma skin cancer
was reported by 8% of cases and 2% of controls.Separate contribution of MC1R genotype and traditional
factors
Compared to the base model, the separate addition of
MC1R, pigmentation score, nevi, non-melanoma skin
cancer and solar lentigines each considerably improved
the discriminative ability of the model, whereas inclusion
of self-reported sun and sunbed exposure variables
(childhood sun exposure, childhood blistering sunburns
and lifetime sunbed use) resulted in minimal improve-
ment, and inclusion of family history resulted in no im-
provement (Table 2).
When added to the base model, MC1R improved the
AUC by 6%, sensitivity by 12% (95% CI 5-19%), specifi-
city by 14% (95% CI 6-23%), and improved the quartile
classification for a net 26% (95% CI 15-37%) of partici-
pants. Further examination showed that the six ‘R’ var-
iants were responsible for most of the improvement to
risk prediction, as together they increased the AUC by
4% (P = 0.001) and improved the quartile classification
by a net 21% (95% CI 10-31%) of participants whereas
the combined ‘r’ variants increased the AUC by less than
1% (P = 0.5) and the net reclassification improvement by
5% (−3-12%) (Table 2).
The contribution of traditional pigmentation charac-
teristics to model improvement was similar for self-
reported and the more objectively-measured pigmenta-
tion score. Physician-counted number of nevi ≥ 2 mm
and 2–5 mm were the nevi variables most predictive of
melanoma risk, whereas self-reported number of nevi
had a more modest impact. There was no material change
to any of our results in this paper when we repeated the
models, replacing the single composite ‘pigmentation
score’ variable with the six separate variables that com-
prise the pigmentation score (data not shown). We also
tested hair colour as a separate variable and found that it
Table 1 Demographic characteristics and selected risk





Male (%) 36 42
Female (%) 64 58
Median age in years1 (median, IQR) 33 (28–37) 35 (31–39)
European ancestry (%)
British or northern European 75 60
Southern European 4 7
Other European or unknown 21 33
MC1R (%)
Wild-type consensus alleles only 15 29
r only alleles 27 32
Any R allele 58 40
Number of nevi≥ 2 mm (median, IQR) 205 (108–320) 67 (28–158)




Previous non-melanoma skin cancer (%) 8 2
Confirmed family history of melanoma (%) 10 5
Pigmentation score, self-reported (%)
1st quartile (lower risk) 8 24
2nd quartile 26 26
3rd quartile 24 25
4th quartile (higher risk) 42 25
Number of childhood blistering
sunburns (%)
0 65 69
≤ 8 17 19
> 8 18 12
Number of lifetime sunbed sessions (%)
0 76 80
1–10 14 14
> 10 10 6
IQR interquartile range.
1 Age at diagnosis for cases and age at interview for controls.
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the pigmentation score variable.
Incremental contribution of MC1R genotype and
traditional factors
In a more extensive multivariate model where each risk
factor was added incrementally to the base model in
order of their contribution to increasing the AUC, only
MC1R, number of nevi and history of non-melanoma
skin cancer significantly improved the AUC for both the
self-reported and physician-measured models (Table 3).Self-reported pigmentation score weakly increased (by 1%;
P = 0.07) the AUC for the self-reported model already
containing MC1R, nevi and non-melanoma skin cancer,
whereas more objectively-measured pigmentation score
did not increase the discrimination of the corresponding
physician-measured model. MC1R and number of nevi
were the only variables that produced significant quartile
reclassification of cases and controls. Measures of sun and
sunbed exposure and solar lentigines did not increase the
discrimination of the models already containing the other
factors; nor did number of dysplastic nevi or raised nevi,
once number of nevi ≥ 2 mm (the most predictive nevus
variable) was included in the physician-measured model.Selection and validation of final models, and measures of
model performance
Based on improvement to the AUC, the final selected
models for both the self-reported and physician-mea-
sured models included MC1R, nevi and non-melanoma
skin cancer, in addition to demographic factors. Details
of the models’ performance and validation are shown
in Table 4. The AUC was higher for the physician-
measured model (0.83, 95% CI 0.80-0.86) than for the
self-reported model (0.78, 95% CI 0.75-0.82), a diffe-
rence in the AUC of 0.043 (P < 0.001), reflecting bet-
ter predictive ability of clinically-measured number of
nevi than self-reported nevi.
Compared to the base model, the self-reported model
improved classification for a net 37% (95% CI 25-48%)
of participants based on quartile cut-points and 63%
(95% CI 47-78%) using the category-free approach; for
the physician-measured model, net reclassification im-
provement was 53% (95% CI 41-64%) and 85% (95% CI
70-101%), respectively. Overall model performance also
improved: Nagelkerke’s R2 increased from 13% in the
base model to 32% for the self-reported model and 39%
for the physician-measured model, and the Brier score
decreased. Internal validation produced similar results
for Nagelkerke’s R2 and the AUC. The discrimination
slopes for each model (presented as box plots in
Additional file 1: Figure S1), show how the physician-
measured model achieved the best separation of pre-
dicted probabilities between cases and controls.
External validation of the final regression models using
data from the English study showed slightly lower dis-
crimination for the self-reported and physician-mea-
sured models compared to our Australian study results.
However, this appeared to be due to lower discrimin-
ation for the baseline model (AUC 0.61 compared to
0.67), as both studies demonstrated similar improve-
ments to the AUC, NRI and Nagelkerke’s R2 for the self-
reported and physician-measured models when com-
pared to the respective base model (Table 4). For both
Table 2 Separate contributions of MC1R genotype, and self-reported and physician-measured traditional factors to risk prediction of melanoma, measured
using the area under the receiver operating characteristic curve (AUC) and net reclassification improvement (NRI)








NRI (95% CI) P5 NRI (95% CI) P5 NRI (95% CI) P5
Base model with demographic6 factors only 0.67 (0.63, 0.72)
MC1R all variants7 0.73 (0.69, 0.77) 0.058 <0.001 0.12 (0.05, 0.19) 0.001 0.14 (0.06, 0.23) <0.001 0.26 (0.15, 0.37) <0.001
‘R’ variants only 0.72 (0.68, 0.75) 0.041 0.001 0.04 (−0.03, 0.11) 0.25 0.17 (0.09, 0.25) <0.001 0.21 (0.10, 0.31) <0.001
‘r’ variants only 0.68 (0.64, 0.72) 0.004 0.48 0.03 (−0.02, 0.07) 0.28 0.02 (−0.04, 0.08) 0.52 0.05 (−0.03, 0.12) 0.24
Self-reported risk factors
Nevi (none, few, some, many) 0.72 (0.68, 0.76) 0.048 0.001 0.15 (0.07, 0.23) <0.001 0.09 (−0.00, 0.18) 0.06 0.24 (0.12, 0.36) <0.001
Pigmentation score8 0.73 (0.69, 0.77) 0.053 <0.001 0.09 (0.03, 0.16) 0.004 0.12 (0.04, 0.20) 0.003 0.22 (0.11, 0.32) <0.001
Sun & sunbed exposure9 0.69 (0.65, 0.73) 0.015 0.06 0.04 (−0.01, 0.09) 0.1 0.04 (−0.02, 0.10) 0.2 0.08 (0.00, 0.16) 0.04
Family history10 0.68 (0.64, 0.72) 0.006 0.4 0.01 (−0.02, 0.04) 0.6 0.03 (−0.01, 0.07) 0.2 0.04 (−0.01, 0.09) 0.2
Non-melanoma skin cancer11 0.70 (0.66, 0.74) 0.024 0.003 −0.03 (−0.06, 0.01) 0.2 0.09 (0.05, 0.13) <0.001 0.06 (0.01, 0.12) 0.02
Physician-measured risk factors
Nevi 2+ mm 0.79 (0.75, 0.82) 0.111 <0.001 0.10 (0.03, 0.17) 0.008 0.29 (0.20, 0.38) <0.001 0.39 (0.28, 0.51) <0.001
Nevi 2–5 mm 0.78 (0.75, 0.82) 0.108 <0.001 0.10 (0.03, 0.17) 0.006 0.30 (0.21, 0.39) <0.001 0.40 (0.29, 0.52) <0.001
Nevi 5+ mm 0.76 (0.72, 0.79) 0.082 <0.001 −0.01 (−0.08, 0.06) 0.8 0.33 (0.25, 0.42) <0.001 0.32 (0.21, 0.44) <0.001
Nevi dysplastic 0.70 (0.66, 0.74) 0.027 0.01 −0.04 (−0.10, 0.01) 0.1 0.15 (0.09, 0.21) <0.001 0.10 (0.02, 0.19) 0.02
Nevi raised 0.74 (0.70, 0.77) 0.061 <0.001 −0.04 (−0.11, 0.03) 0.2 0.29 (0.21, 0.36) <0.001 0.24 (0.14, 0.35) <0.001
Pigmentation score12 0.72 (0.68, 0.76) 0.047 0.001 0.11 (0.04, 0.17) 0.001 0.09 (0.01, 0.17) 0.03 0.20 (0.09, 0.30) <0.001
Solar lentigines 0.74 (0.70, 0.78) 0.063 <0.001 0.09 (0.02, 0.16) 0.01 0.17 (0.08, 0.26) <0.001 0.26 (0.15, 0.37) <0.001
AUC Area under the receiver operating characteristic curve, NRI Net reclassification improvement.
1 Each risk factor was separately added to the ‘base model’ to evaluate its influence on risk prediction.
2 The change in the AUC between the base model and the model with the additional risk factor included.
3 Chi-square p-value for the difference in the AUC when compared to the base model.
4 Based on quartile cut-points. Improvement in sensitivity is calculated from reclassification of cases, improvement in specificity is calculated from reclassification of controls, and the overall improvement in
classification combines the improvements in sensitivity and specificity.
5 The p-value, representing the statistical significance of the NRI, was calculated using the methods of Pencina et al. [29].
6 Demographic factors include age, sex, city of recruitment and European ancestry.
7 MC1R is included as separate continuous variables for each of the six ‘R’ variants and one combined ‘r’ variant variable.
8 Self-reported ‘pigmentation score’ is a continuous variable derived from several self-reported variables including: ability to tan, propensity to sunburn, skin colour, eye colour, hair colour and childhood freckling.
9 ‘Sun & sunbed exposure’ includes total childhood sun exposure hours (quartiles), childhood blistering sunburns (none, ≤ 8, > 8), and lifetime number of sunbed sessions (0, 1–10, >10).
10 Confirmed family history of melanoma in a first degree relative (yes/no).
11 A self-reported previous diagnosis of non-melanoma skin cancer.
12 Objectively-measured ‘pigmentation score’ is a continuous variable derived from objectively-measured: hair colour, eye colour and skin reflectance (inner arm b* measure), and self-reported: ability to tan, propensity


















Table 3 Forward stepwise models showing the incremental contribution of MC1R genotype and traditional risk factors to risk prediction models for












NRI (95% CI) P NRI (95% CI) P NRI (95% CI) P
Base model 0.67 (0.63, 0.72)
Self-reported model: including only self-reported nevus and phenotype risk factors
MC1R all variants 0.73 (0.69, 0.77) 0.058 <0.001 0.12 (0.05, 0.19) 0.001 0.14 (0.06, 0.23) <0.001 0.26 (0.15, 0.37) <0.001
Nevi (none, few, some many) 0.77 (0.73, 0.81) 0.038 0.001 0.14 (0.07, 0.20) <0.001 −0.00 (−0.09, 0.08) 0.93 0.13 (0.02, 0.24) 0.02
Non-melanoma skin cancer 0.78 (0.75, 0.82) 0.012 0.02 −0.02 (−0.06, 0.01) 0.2 0.05 (0.01, 0.08) 0.01 0.02 (−0.03, 0.07) 0.4
Pigmentation score 0.79 (0.76, 0.83) 0.009 0.07 0.04 (−0.01, 0.08) 0.1 0.02 (−0.04, 0.08) 0.5 0.06 (−0.02, 0.13) 0.1
Sun & sunbed exposure 0.80 (0.76, 0.83) 0.004 0.4 0.02 (−0.02, 0.06) 0.4 0.03 (−0.02, 0.09) 0.2 0.05 (−0.01, 0.12) 0.1
Family history 0.80 (0.76, 0.83) 0.001 0.7 0.00 (−0.02, 0.03) 0.9 0.00 (−0.02, 0.03) 0.8 0.01 (−0.03, 0.04) 0.7
Physician-measured model: including physician-measured nevus and phenotype risk factors where available
Nevi 2+ mm5 0.79 (0.75, 0.82) 0.111 <0.001 0.10 (0.03, 0.17) 0.008 0.29 (0.20, 0.38) <0.001 0.39 (0.28, 0.51) <0.001
MC1R all variants 0.82 (0.78, 0.85) 0.031 0.002 0.05 (−0.01, 0.10) 0.1 0.09 (0.02, 0.15) 0.007 0.13 (0.05, 0.22) 0.002
Non-melanoma skin cancer 0.83 (0.80, 0.86) 0.010 0.02 −0.01 (−0.04, 0.02) 0.4 0.03 (0.01, 0.06) 0.02 0.02 (−0.02, 0.06) 0.3
Pigmentation score5 0.83 (0.80, 0.86) 0.003 0.5 0.01 (−0.03, 0.05) 0.6 −0.03 (−0.08, 0.02) 0.2 −0.02 (−0.08, 0.04) 0.5
Solar lentigines5 0.83 (0.80, 0.86) 0.004 0.3 0.03 (−0.01, 0.07) 0.10 −0.01 (−0.05, 0.03) 0.7 0.02 (−0.03, 0.08) 0.4
Family history 0.83 (0.80, 0.86) <0.001 1.0 0.00 (−0.01, 0.02) 0.5 −0.01 (−0.03, 0.01) 0.5 −0.00 (−0.03, 0.02) 0.8
AUC Area under the receiver operating characteristic curve, NRI Net reclassification improvement.
1 Each risk factor was added in a forward stepwise manner in order of their contribution to improving the AUC. The base model and individual risk factors are described in Table 2 footnotes.
2 The change in the AUC from the previous (incremental) model.
3 Chi-square p-value for the difference in the AUC when compared to the previous (incremental) model.
4 Based on quartile cut-points. Improvement in sensitivity is calculated from reclassification of cases, improvement in specificity is calculated from reclassification of controls, and the overall improvement in
classification combines the improvements in sensitivity and specificity.


















Table 4 Performance measures for the final selected self-reported and physician-measured risk prediction models for
melanoma that include MC1R, nevi and non-melanoma skin cancer
Performance measure Base model1 Self-reported model1 Physician-measured model1
Discrimination
AUC (95% CI) 0.67 (0.63, 0.72) 0.78 (0.75, 0.82) 0.83 (0.80, 0.86)
Change in AUC from the base model 0.108 (P <0.001) 0.152 (P <0.001)
Discrimination slope 0.099 0.242 0.306
Integrated discrimination index (IDI) 0.143 0.207
Sensitivity, given a specificity of 90% 23% 40% 53%
Reclassification (compared to the base model)
NRI (95% CI) based on quartile categories
Improvement in sensitivity 0.20 (0.13, 0.27) 0.20 (0.12, 0.27)
Improvement in specificity 0.17 (0.08, 0.26) 0.33 (0.24, 0.42)
Overall improvement in classification 0.37 (0.25, 0.48) 0.53 (0.41, 0.64)
Category-free NRI
Improvement in sensitivity 0.33 (0.23, 0.42) 0.32 (0.23, 0.42)
Improvement in specificity 0.30 (0.18, 0.42) 0.53 (0.41, 0.65)
Overall improvement in classification 0.63 (0.47, 0.78) 0.85 (0.70, 1.01)
Calibration
Hosmer-Lemeshow test P value 0.68 0.72 0.01
Overall performance
Nagelkerke’s R2 0.131 0.315 0.393
Brier score 0.214 0.180 0.164
Internal validation
Nagelkerke’s R2 (95% CI) 0.14 (0.09, 0.19) 0.34 (0.28, 0.41) 0.41 (0.35, 0.47)
AUC (95% CI) 0.68 (0.64, 0.71) 0.79 (0.76, 0.83) 0.83 (0.81, 0.86)
External validation using data from English study
AUC (95% CI) 0.61 (0.57, 0.64) 0.71 (0.68, 0.74) 0.79 (0.76, 0.81)
Change in AUC from the base model 0.105 0.182
Discrimination slope 0.035 0.126 0.219
NRI (95% CI) based on quartile categories
Improvement in sensitivity 0.20 (0.14, 0.25) 0.12 (0.07, 0.18)
Improvement in specificity 0.11 (0.04, 0.18) 0.34 (0.27, 0.41)
Overall improvement in classification 0.30 (0.22, 0.39) 0.46 (0.37, 0.55)
Hosmer-Lemeshow test P value 0.17 0.39 0.0003
Nagelkerke’s R2 0.050 0.166 0.303
Brier score 0.220 0.199 0.176
AUC Area under the receiver operating characteristic curve, NRI Net reclassification improvement.
1 The base model included demographic factors age, sex, city of recruitment and European ancestry. Both the self-reported model and the physician-measured
model included the variables from the base model plus MC1R, non-melanoma skin cancer and nevi (categorised as ‘none, few some, many’ in the self-reported
model, and as a continuous variable ‘the number of nevi ≥ 2 mm’ in the physician-measured model.
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bration (P <0.05) for the physician-measured model.
Using ROC curves (Figure 1), we estimated the pro-
portion of cases and controls that would be classified as
high-risk using different cut-points. Choosing a cut-point
value of 90% specificity, equating to 10% of controls beingclassified as high-risk, the proportion of cases identi-
fied as high-risk (i.e. sensitivity) was 23% in the base
model, 40% in the self-reported model, and 53% in
the physician-measured model. When we chose a dif-
ferent cut-point based on a balance of sensitivity and
specificity (by selecting the value in the top, left-hand
Figure 1 Receiver operating characteristic (ROC) curves for the
base, self-reported and physician-measured final models.
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each 62% in the base model, 70% in the self-reported
model and 74% in the physician-measured model.
OR estimates
OR estimates for MC1R, nevi and non-melanoma skin
cancer are presented in Table 5. Previously, we observed
a stronger association between MC1R and melanoma for
men than women in this study (P = 0.005) [15]; in this
analysis the multivariate OR for any R allele compared toTable 5 Odds ratios for melanoma associated with MC1R, nev
Predictor Cases Co
MC1R3
Wild-type consensus alleles only 62
r only alleles 112
Any R allele 239 1
Number of physician-measured nevi ≥ 2 mm4






Previous non-melanoma skin cancer
No 382 2
Yes 31
1 Adjusted for age, sex, city of recruitment, and European ancestry.
2 Adjusted for age, sex, city of recruitment, European ancestry and other variables i
3 The categories are mutually exclusive. Silent changes (i.e. changes that are synony
4 Counted by a dermatology trainee.wild-type consensus alleles was 4.20 (95% CI 1.75-10.10)
for men and 2.44 (95% CI 1.31-4.56) for women.
Incremental contribution of MC1R genotype to a model
including traditional pigmentation variables, nevi and
non-melanoma skin cancer
We assessed whether MC1R further improved prediction
of melanoma when traditional pigmentation characteris-
tics were already in the model, by replacing MC1R with
‘pigmentation score’ in the final regression models and
then testing the addition of MC1R. We found that
MC1R increased the AUC by 2.1% (from 0.77 to 0.79,
P = 0.01) for the self-reported model and 1.3% (from
0.82 to 0.83, P = 0.04) for the physician-measured model;
and improved the quartile classification for a net 10%
(95% CI 1-18%, P = 0.03) of participants for the self-
reported model and 6% (95% CI −1-13%, P = 0.08) for the
physician-measured model (data not shown in tables).
Discussion
MC1R, nevi and personal history of non-melanoma skin
cancer were identified as the strongest predictors of mel-
anoma risk in our study of early-onset melanoma. The
contribution of MC1R to prediction of melanoma was
similar to that obtained from measuring self-reported
nevi, which is considered a strong and discriminative
risk factor [5,33,34]. When added separately to the base
model, MC1R and self-reported nevi increased the AUC
by 6% and 5% respectively, and both improved classifi-
cation for about a quarter of the cases and controls
through net movement of cases into higher quartiles andi and non-melanoma skin cancer
ntrols Minimally-adjusted
odds ratio1 (95% CI)
Multivariate-adjusted
odds ratio2 (95% CI)
76 1.00 1.00
83 1.86 (1.16, 2.96) 1.72 (1.02, 2.89)
04 2.91 (1.88, 4.50) 2.94 (1.80, 4.80)
63 1.08 (1.06, 1.09) 1.08 (1.06, 1.10)
18 1.00 1.00
35 0.68 (0.33, 1.42) 0.70 (0.32, 1.50)
82 1.78 (0.85, 3.71) 2.01 (0.93, 4.36)
28 2.71 (1.21, 6.10) 2.87 (1.23, 6.70)
59 1.00 1.00
4 8.84 (2.83, 27.63) 8.59 (2.68, 27.47)
n the table (except nevi variables not adjusted for each other).
mous or occur in non-coding regions) are counted as consensus alleles.
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number of nevi measured by physicians (dermatology
trainees) was the strongest predictor of risk overall,
increasing the AUC by 11% and reclassifying 39% of
participants. Although MC1R genotype is strongly as-
sociated with skin and hair phenotype [12,14], it was a
better predictor of early-onset melanoma than was pig-
mentation characteristics.
Our models demonstrated high discrimination: an
AUC of 0.78 for the self-reported model and 0.83 for the
physician-measured model in the Australian (develop-
ment) dataset and 0.71 and 0.79 in the English (valid-
ation) dataset. The additional predictive value of MC1R,
nevi and non-melanoma skin cancer variables when
added to the demographic ‘base’ model was similar for
both studies, suggesting good generalisability of our re-
sults to other genetically similar populations. The differ-
ences in the AUC for the base models of the two studies
is less important, as it is strongly influenced by how age,
sex, ethnic and regional differences have already been
accounted for in the study design. It is expected that
models will perform better on the development dataset
than the validation dataset because of overfitting.
Three other, preliminary, melanoma risk prediction
models containing MC1R genotype have been published.
Whiteman and Green [16] published a prototype for a
melanoma risk prediction tool but provided no details
on predictive performance. In a published conference ab-
stract, Smith et al. [17] showed an AUC of 0.72 (95% CI
0.70-0.75) for a model containing conventional risk factors
and 0.75 (95% CI 0.72-0.77) when they added MC1R
genotype, outdoor UV and indoor UV exposure, based on
data from a case–control study of people aged 25–59 years
in Minnesota. In a Greek study with 284 cases and 284
controls, Stefanaki and colleagues [18] derived a melan-
oma risk prediction model containing phenotypic traits
(except nevi was not available) and 8 single nucleotide
polymorphisms (SNPs) from several genes that included
the MC1R locus. They found no appreciable change to the
AUC after the addition of the 8 SNPs (AUC changed from
0.833 to 0.839), which they suggested may have been
partly due to lower risk allele frequencies in their Greek
population compared to other European populations [18].
Measurement of single SNPs rather than the causal vari-
ants might also underestimate the contribution of genetic
variation to melanoma risk.
Other published risk prediction models for melanoma
have reported AUCs in the range of 0.54 to 0.86 [34-41].
The highest reported AUC of 0.86 was for a model
containing age, hair colour, personal history of melano-
ma and suspicious melanocytic lesion on dermoscopy,
developed using a German cohort [36]. We were not
able to include personal history of melanoma in our
models because the study eligibility criteria specificallyexcluded these cases; however previous primary melan-
oma would be rare in people younger than 40 years and
thus would be less relevant to our analysis than in stud-
ies with older participants. Previous non-melanoma skin
cancer was a very strong risk factor in our study (OR 9),
however because it had a low prevalence, the contri-
bution to the AUC and more particularly to NRI was
modest. This can be a limitation of these prediction
methods, as factors that increase risk substantially can
have minimal overall improvement to the model if they
are rare. Another risk factor affected in this way is family
history of melanoma. This variable did not improve dis-
crimination in our analysis. We used a relatively low
threshold for defining positive family history, requiring
only one confirmed melanoma in a first-degree relative.
This definition is consistent with many other population-
based studies [7] and is associated with approximately
two-fold increased melanoma risk [7,19]. However, a more
extensive family history is associated with higher risk esti-
mates [42] and thus, for some individuals, this factor will
strongly influence their personal melanoma risk. This
issue demonstrates the different priorities that are placed
on the design of risk prediction tools for different settings:
one type for stratifying the population into broad risk
categories to aid primary prevention strategies, and
the other type for more precisely estimating personal
risk of melanoma.
Harbauer et al. [38] developed a model containing num-
ber of nevi, skin phototype and skin UV damage, adjusted
for age and sex, with an AUC of 0.73 (95% CI 0.68-0.77)
when measured by self-report and 0.77 (95% CI 0.73-0.83)
when measured by a dermatologist. Similarly, our physi-
cian-measured model also achieved better discrimination
than our self-report model, which was due solely to im-
proved measurement of nevi. Our results indicate that
counting all nevi greater than 2 mm is a better predi-
ctor of melanoma than counting only large, dysplastic
or raised nevi. There was no added benefit to having
physicians measure hair colour, eye colour or skin
colour, as the discriminative ability of the pigmen-
tation score was similar whether measured by self-
report or by a physician.
Including sun and sunbed exposure variables resulted
in little improvement to discrimination; when added
as a group to the base model, they increased the
AUC by 1.5%, but this diminished when the other
factors were in the model. Although these sun and
sunbed exposures have been shown to be associated
with melanoma in our study [21,43], it has been dem-
onstrated that very strong, independent associations
with risk are required to meaningfully increase the
AUC [29,44,45]. Sun exposure-related factors gener-
ally do not have very strong effect estimates, which
may be partly due to inherent difficulties measuring
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fluence of genetically determined risk factors.
The Hosmer-Lemeshow test of calibration indicated
poor agreement between observed and predicted out-
comes for the physician-measured model, for both the
development and external validation datasets. We exam-
ined the observed and expected values within each decile
from the Hosmer-Lemeshow test but there no was con-
sistent pattern describing the differences. Calibration has
been rarely reported for other published melanoma risk
prediction models. A prospective cohort study with
follow-up of individuals for development of melanoma
would be the ideal method to evaluate melanoma predic-
tion probabilities.
Several strengths and limitations of the Australian
Melanoma Family Study have been discussed previously
[15,19,21]. We had low participation from cases and
population controls, which is a common problem for
population-based studies [46], especially when conduc-
ted with highly mobile, young adults [47]. Although poor
participation can sometimes lead to selection bias [46],
we did not find strong evidence of this occurring in our
study [19]. This analysis was restricted to participants
who had a complete set of data for self-reported and
clinically-measured risk factors. Having a clinical skin
examination was a preferred but not compulsory aspect
of participation in the Australian Melanoma Family
Study, and thus was only completed by a subset of case
and control participants. Although this reduced the sam-
ple size for our analysis, it is unlikely to have introduced
systematic bias, as a comparison of those with (n = 676)
versus without (n = 270) clinical skin examinations
showed no statistically significant differences on pre-
dictors including sex, self-reported nevi, hair colour,
MC1R genotype, previous non-melanoma skin cancer,
and childhood blistering sunburns.
Our study focused on prediction of early-onset melan-
oma. A younger age at diagnosis is more likely to reflect
an underlying genetic susceptibility to the disease, thus
the contribution of MC1R and traditional factors to risk
prediction in our study may differ for those diagnosed at
older ages or for other ethnicities. Nevertheless, our ex-
ternal validation results do suggest generalisability of our
results to a broader-aged population. The generalisability
of our results may also differ by country and the pheno-
typic and behavioural characteristics of the population.
External validation of risk prediction models using an in-
dependent dataset has been rarely performed by other
studies, and is an important strength of our study.
Conclusions
Physician-measured nevi, MC1R genotype and previous
non-melanoma skin cancer were the strongest predictors
of early-onset melanoma in this study. Our resultssuggest that there might be modest benefit to measuring
MC1R genotype for risk prediction even if information
about traditional self-reported or clinically measured
pigmentation characteristics and nevi is already available.
Although many nonsynonymous MC1R gene variants
exist [10,48], the six ‘R’ variants were responsible for
most of the improvement to risk prediction in this study
and thus would be the most important MC1R gene vari-
ants to include in melanoma prediction tools if it was
not feasible or economically justifiable to measure all
variants. We had limited statistical power to evaluate the
predictive effect of individual R variants, however both
our previous study [15] and a meta-analysis [14] attributed
the R151C variant with the highest population burden
based on prevalence and relative risk of melanoma.
Our study results will help guide the development of
melanoma risk prediction tools that incorporate MC1R
genotype. Decreasing genotyping costs and increasing
use of genetic testing is making it more feasible to in-
corporate genetic risk factors into clinical risk prediction
tools; however, translation into routine clinical practice
requires several additional steps [49,50]. As a screening
tool, evidence is needed to show whether or not individ-
uals identified at high risk of melanoma will improve
their sun-protection behaviours and perform regular
skin checks, that improved outcomes justify the associ-
ated costs, and that the benefits of obtaining this in-
formation outweigh any disadvantages for patients and
their families. For clinical genetic counselling, informa-
tion on common variants in other melanoma suscepti-
bility genes may need to be incorporated in the risk
prediction tool in order to more precisely estimate per-
sonal risk of melanoma. Ultimately, the clinical and public
health value of such tools will depend not only on its pre-
dictive performance, but also on the application setting,
feasibility, cost effectiveness, benefits and harms [51,52].
Additional file
Additional file 1: Figure S1. Box-and-whisker plots showing the
predicted probabilities of melanoma for cases and controls for the
A. Base, B. Self-reported and C. Physician-measured final models. The
discrimination slope is calculated as the difference between the mean
predicted probability of melanoma for cases and controls. The box
represents the median and interquartile range, and the bars indicate the
range. The base model includes demographic factors age, sex, city of
recruitment and European ancestry. Both the self-reported model and
the physician-measured model also include MC1R, non-melanoma skin
cancer and nevi (self-reported model = none, few, some, many;
physician-measured model = number of nevi ≥ 2 mm).
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